Apatinib, an oral small-molecule TKI that selectively targets VEGFR-2, has displayed clinical benefit in patients with advanced NSCLC when combined with chemotherapy or EGFR-TKIs [19, 23]. Here, EGFR is linked to non-small cell lung carcinoma.